SIGA Technologies Inc. (SIGA) is a pharmaceutical company that specializes in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is publicly traded under the ticker "SIGA" on the NASDAQ exchange. Since its inception in the mid-1990s, SIGA Technologies has been dedicated to improving health security, both domestically and globally, through the introduction of innovative therapeutics.
The primary focus of SIGA Technologies is creating antiviral therapies for high-consequence, viral infectious diseases. This unerring dedication to combating biothreats has shaped the company's rigorous approach to research and development, thus making them a leader in their field.
The cornerstone of SIGA’s product pipeline is TPOXX® (tecovirimat), the first-ever drug with an indication for the treatment of smallpox. The U.S. Food and Drug Administration (FDA) approved TPOXX in 2018, marking a significant milestone in global health security. Since smallpox is considered a potential bioterrorism threat, TPOXX's introduction has been highly commendable and well-received within the public health sector.
Its commitment to medical advancement does not stop there. SIGA Technologies is also actively involved in conducting multiple pre-clinical programs aimed at addressing other biothreats. Through collaboration with governmental, non-governmental, and commercial entities, SIGA aims to combat emerging viral diseases and potential bioterrorism threats.
In addition to their dedication to public health and safety, SIGA Technologies is committed to creating value for its shareholders. Their strategic partnerships with entities such as the Biomedical Advanced Research and Development Authority and U.S. Department of Defense underscore their ability to deliver on shared objectives.
On the corporate side, SIGA Technologies boasts a diverse workforce and a leadership team that combines broad industry knowledge with a history of innovative solutions. Its guiding principles emphasize ethical business practices and integrity in all aspects of their business, from research to manufacturing.
In conclusion, SIGA Technologies is a company that operates at the forefront of health security, addressing critical unmet medical needs by utilizing its expertise in drug discovery, development, and commercialization. By addressing biothreats and ensuring its commitment to shareholders and ethics, SIGA Technologies continues to underline its pivotal role within the global healthcare landscape.